ACUPAN (nefopam) - Treatment of acute pain
Reason for request
Summary of opinion
Favourable opinion for reimbursement in the “Symptomatic treatment of acute painful conditions, especially post-operative pains”.
No clinical added value of the new form compared to the forms already available (ACUPAN 20 mg/2 mL solution for injection and its generics, and NEFOPAM PANPHARMA 30 mg film-coated tablets).
Clinical Benefit
Moderate |
The Committee considers that the clinical benefit of ACUPAN 30 mg tablets (nefopam) is moderate in the MA indication. |
Clinical Added Value
no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed (ACUPAN 20 mg/2 mL solution for injection and its generics, and NEFOPAM PANPHARMA 30 mg film-coated tablets). The Committee highlights the fact that nefopam has no MA in chronic pain. |